Spago Nanomedical AB (publ), a nanomedicine company, engages in the development projects based on a platform of polymeric materials for diagnosis and treatment of life-threatening and debilitating diseases in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment of liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of cancer. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. The company was incorporated in 1999 and is based in Lund, Sweden.